entertainment -WSS

entertainment

author：entertainment 2025-09-11 10:29:13 - browse：9

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Cord blood banking comes at a high cost to babies

WSS

Letters to First Opinion on caregivers, digital health, and more

Ionis drug prevents swelling attacks due to hereditary angioedema

Why hospitals are withdrawing from US News rankings

BMI, flaws aside, is found to be useful estimate of body fat in youth

How Medicaid coverage policies for immigrants impact new moms

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

entertainment

hotspot

What does generative AI mean for health care? We asked experts

Ionis drug prevents swelling attacks due to hereditary angioedema

Bright Health sells Medicare Advantage business to Molina

A public scorecard can help hold safety

Supreme Court strikes down use of affirmative action

How dance can help nurses traumatized by Covid

In age of alternative facts, a scholarly course on calling out crap

Medicare has a new plan to address drug shortages

Cancer drug shortages should be causing more outrage

At Orexo, a ‘turning point’ for everything but digital health

hotspot

Cord blood banking comes at a high cost to babies

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Doctors find melanoma drugs effective against rare brain cancer

Why hospitals are withdrawing from US News rankings

Wikipedia

explore

focus

focus